Steps in this run
| Step |
Calls |
Tokens in |
Cache hit |
Cost |
|
response generation
|
20 |
45,597 |
|
$0.23675 |
|
summary generation
|
4 |
14,531 |
|
$0.10800 |
|
search query generation
|
4 |
5,485 |
|
$0.02959 |
|
|
4 |
8,437 |
|
$0.00807 |
|
|
7 |
3,641 |
|
$0.00662 |
All 39 API calls — tap to expand
$0.001490
Est. cost (USD)
Result preview
```json
["vaccine messaging", "hhs credibility", "public health communication", "acip", "immunization schedule", "populist politics", "health policy", "kennedy", "federal health administration", "payer coverage", "vaccine hesitancy", "healthcare regulation", "institutional trust", "measles outbreak", "cabinet communications"]
```
$0.016281
Est. cost (USD)
Result preview
The author's central thesis is that the Kennedy-Bash CNN interview was not merely a communications embarrassment but a policy event revealing a fundamental incompatibility between movement-style populist health messaging and the operational requirements of running HHS — and that this incompatibility has already produced measurable, costly structural damage to the US immunization infrastructure reg
$0.005691
Est. cost (USD)
Result preview
```json
[
"ACIP dissolved reconstituted immunization schedule fragmentation payer coverage",
"\"Vaccines for Children\" program ACIP liability protection schedule disruption Kennedy HHS",
"HHS restructuring 82000 62000 headcount CDC immunization infrastructure cost",
"AAP ACOG IDSA independent immunization schedule federal authority replaced fragmented",
"\"placebo-controlled trial\" vac
$0.002338
Est. cost (USD)
Result preview
```json
["applied behavior analysis", "ABA spending", "medicaid", "utilization management", "prior authorization", "provider credentialing", "payment integrity", "behavioral health", "fraud detection", "BCBA", "healthcare policy", "state medicaid", "treatment authorization", "healthcare technology", "claims billing"]
```
$0.037383
Est. cost (USD)
Result preview
The author's central thesis is that the CMS August 2026 State Medicaid and CHIP ABA Toolkit is functionally a product specification for healthcare software companies, because the 421% growth in ABA Medicaid spending against only 66% growth in children served reveals a structural billing and utilization problem that cannot be solved by policy alone — it requires software infrastructure across utili
$0.008316
Est. cost (USD)
Result preview
```json
[
"ABA Medicaid spending growth billing hours \"utilization management\" BCBA RBT",
"RBT NPI \"rendering provider\" claims attribution ABA Medicaid fraud",
"\"421\" OR \"421 percent\" ABA Medicaid spending children served enrollment gap",
"\"97153\" ABA billing fraud BCBA supervision attribution OR \"session-level\"",
"CMS ABA toolkit \"build spec\" OR \"product roadmap\" softwar
$0.001718
Est. cost (USD)
Result preview
```json
["apoe4 genetics", "alzheimer's risk testing", "direct-to-consumer genomics", "genetic counseling", "lifestyle intervention", "anti-amyloid antibodies", "lecanemab", "genetic privacy", "gina legislation", "plasma biomarkers", "primary care screening", "consumer health marketing", "genetic disease classification", "long-term care insurance", "health equity"]
```
$0.020409
Est. cost (USD)
Result preview
The article's central thesis is that Chris Hemsworth's on-camera APOE4 disclosure in 2022 created massive consumer demand for Alzheimer's genetic testing without any corresponding infrastructure to counsel patients, interpret results responsibly, or intervene meaningfully — and that the gap between public demand and clinical reality is now a structural problem for operators, payers, and clinicians
$0.008082
Est. cost (USD)
Result preview
```json
[
"\"APOE4\" \"genetic counselor\" OR \"counseling\" bottleneck OR workforce OR infrastructure Alzheimer's",
"\"Hemsworth\" APOE4 testing demand OR disclosure OR awareness Alzheimer's genetics",
"APOE4 \"lecanemab\" OR \"anti-amyloid\" ARIA risk homozygous OR \"e4 carriers\"",
"\"APOE4\" ketones OR \"cold plunge\" OR \"brain training\" OR supplements evidence OR \"no evidence\" Alz
$0.002524
Est. cost (USD)
Result preview
```json
["bundled payments", "joint replacement", "medicare policy", "cms reform", "episode-based payment", "orthopedic surgery", "value-based care", "healthcare economics", "quality metrics", "post-acute care", "gainsharing", "surgeon alignment", "prom capture", "remote patient monitoring", "healthcare startups"]
```
$0.033930
Est. cost (USD)
Result preview
The author's central thesis is that CMS's July 31, 2026 finalization of the CJR-X mandatory bundled payment model for joint replacements creates a regulatory-forced infrastructure buildout at 2,000+ hospitals that represents a precise, time-bounded commercial opportunity for B2B healthcare technology startups across five specific solution categories, with the quality scoring gate (not cost managem
$0.007506
Est. cost (USD)
Result preview
```json
[
"\"CJR-X\" PROM capture reconciliation payment",
"\"CJR-X\" bundled payment 2028 hospitals startup",
"\"bundled payment\" \"quality score\" \"PROM\" joint replacement CMS mandatory",
"\"CJR-X\" OR \"CJRX\" gainsharing orthopedic 2026 2027 2028",
"\"PROM capture\" bundled payment reconciliation \"zero\" OR \"disqualified\" OR \"gating\"",
"CMS mandatory bundled payment joint r
$0.003118
Est. cost (USD)
Result preview
```json
[
{
"claim_text": "The Part D Premium Stabilization Demonstration's termination after CY 2026 removes a federal cost cushion while the underlying IRA-restructured benefit economics—which quadrupled plan catastrophic phase liability from 15% to 60%—remain unchanged, creating a structural forcing event.",
"claim_type": "mechanism_explanation"
},
{
"claim_text": "The 6% annu
$0.000726
Est. cost (USD)
Result preview
```json
[]
```
The article contains no extractable claims meeting your criteria. It is purely promotional material with no assertions about healthcare markets, technology, policy, investment, entrepreneurship, AI, or any other substantive topic. The article makes no empirical claims, policy arguments, or mechanistic explanations—only a discount announcement and subject-matter categories. No tweet
$0.000514
Est. cost (USD)
Result preview
```json
[]
```
No claims can be extracted. The article content does not exist (Page not found error), so there are no specific findings, arguments, or positions to extract. Creating fabricated claims would misrepresent the source material.
$0.000366
Est. cost (USD)
Result preview
```json
[]
```
$0.000761
Est. cost (USD)
Result preview
```json
[]
```
The article contains no extractable claims meeting your criteria. As the summary explicitly states, this is a purely administrative notice with no substantive analytical content, arguments, data, findings, or policy positions. The article makes no claims about healthcare, billing mechanisms, subscription models, or any other topic that could be agreed or disagreed with on analytica
$0.000641
Est. cost (USD)
Result preview
```json
[]
```
The article contains no extractable claims meeting your criteria. It is purely promotional content announcing a subscription discount with no assertions about healthcare, markets, technology, or any other substantive topic that could be agreed or disagreed with. There are no empirical claims, policy arguments, or mechanism explanations present in the article to extract.
$0.000499
Est. cost (USD)
Result preview
```json
[]
```
The article content is not available (404 error). No specific, arguable claims can be extracted from missing content. To complete this task, the article must be successfully retrieved and resubmitted.
$0.012417
Est. cost (USD)
Result preview
Tracked this exact supply chain problem for my article on the July PCAC votes, and the contamination concern you're raising is real. The overseas API sourcing issue is documented, not hypothetical.
Here's where it gets complicated though. The 503A bulks list vote everyone celebrated this week doesn't actually fix the supply chain you're describing. What controls whether a compounding pharmacy can
$0.012465
Est. cost (USD)
Result preview
The court's reasoning here is the tell. "Don't compete in the same market" is doing a lot of work in that ruling, and the judge is probably right on the merits. Compounded semaglutide was never really a competitor to Wegovy in any traditional market sense. It was a creature of the shortage exception, legally permitted to exist only because the branded supply couldn't meet demand.
And that's exact
$0.012942
Est. cost (USD)
Result preview
The retention argument is right, and the working conditions piece gets undersold in most policy conversations. But the demographic math makes the timeline brutal regardless of how quickly systems improve conditions. McKinsey's projection of a 450,000 RN shortage by mid-decade isn't primarily a retention artifact, it's a pipeline and age cohort problem that better workplaces alone can't outrun.
Wh
$0.009486
Est. cost (USD)
Result preview
Disenrollment errors during implementation are almost guaranteed to get worse before they get better, and the pregnant woman exception is one of the cleaner cases to adjudicate. The harder problem is that states have to process discharge summaries, volunteer logs, hardship attestations, and school enrollment letters through eligibility systems that were never built for document classification at t
$0.011706
Est. cost (USD)
Result preview
The reliable information requirement is what makes that question so hard to answer, and it's not getting enough attention.
Before a state can even send that enrollee a notice, it's supposed to ingest payroll, workforce, and higher education data to confirm compliance first. But the exception side is just as broken. Medically frail, disaster hardship, hospitalization, each of those exclusion categ
$0.008169
Est. cost (USD)
Result preview
The post you're responding to isn't visible to me, so I can't write a reply that connects it to your article.
Could you paste the text of the post you want to reply to? Once I can see what it actually says, I can write something that engages with it directly and links back to your article.
$0.012627
Est. cost (USD)
Result preview
...and the "reasons not to pay" part is where the analysis has to go one layer deeper, because the reasons themselves aren't actually written by the insurer.
When a plan denies something as "not medically necessary," that clinical determination is almost always running through criteria purchased from InterQual (Optum, roughly 60% of the prior auth market) or MCG (Hearst, roughly 30%). The payer i
$0.012960
Est. cost (USD)
Result preview
Ran an MCP-FHIR prototype on a SMART Health IT sandbox last year where the agent kept pulling organ volume measurements that had no audit trail connecting back to the user who authorized the query. TotalSegmentator via MCP is a sharper version of the same problem: the agent now has enough clinical reasoning to write a hepatosplenomegaly interpretation, but the question of who owns that interpretat
$0.011748
Est. cost (USD)
Result preview
Praising the coordination is fair, but the number doing the most work here is $203.3M against a $900B program, which is 0.02%. I wrote about exactly this at https://www.onhealthcare.tech/p/the-medicaid-fraud-war-room-stopped-4f8?utm_source=x&utm_medium=reply&utm_content=2085827491147432264&utm_campaign=the-medicaid-fraud-war-room-stopped-4f8 and the argument I kept coming back to is that the dolla
$0.011124
Est. cost (USD)
Result preview
Losing on purpose is a serious claim, and the arbitration data makes it harder to dismiss than it sounds. Provider win rates ran around 81% in 2023 and climbed to roughly 88% in early 2025, with median awards landing near 445% of the Qualifying Payment Amount by 2024. At those numbers, a payer strategy of deliberate loss only works if the downstream policy payoff, congressional sympathy, regulator
$0.011856
Est. cost (USD)
Result preview
Reimbursement has the same problem, maybe a harder one.
Even if FDA clears a pathway for aging as an indication, you still land in a world where CMS has no mechanism to price a one-time intervention that offsets costs across decades and multiple disease categories. The actuarial math doesn't fit any existing bucket.
I ran into this exact wall writing about CASGEVY. Approved, clinically effective
$0.010158
Est. cost (USD)
Result preview
The TrialTranslator study found that roughly one in five real-world oncology patients wouldn't even qualify for a phase 3 trial, which means the evidence we're generating at billion-dollar cost is systematically unrepresentative of the patients who'll actually receive the drug.
The expense isn't the core problem. The mismatch between trial populations and real-world populations is.
We've added d
$0.013047
Est. cost (USD)
Result preview
Vance is describing the exact infrastructure problem I documented in the War Room analysis. The $203.3M in flagged Medicaid payments over 88 days sounds significant until you realize the detection ceiling is set by the data substrate, not the analytics. Fragmented, incomplete provider and claims records across 50 state systems is what limits how much fraud even a well-resourced federal operation c
$0.011328
Est. cost (USD)
Result preview
The "AI finds the cure hidden in existing data" narrative keeps getting the constraint wrong, and this post names it clearly. What I'd add from looking at Biomni specifically: even the most capable execution agents (the ones that can actually run the workflow end-to-end) are bottlenecked by exactly what's described here, which is that the biology is under-measured, not under-reasoned. A model that
$0.012012
Est. cost (USD)
Result preview
This case will surface in every payer and reinsurer conversation about long-duration follow-up requirements for gene therapies, and the timing is difficult given where approvals are right now.
The FDA's April 2026 draft guidance on NGS-based safety assessment for genome editing products was already creating demand for a regulated off-target analytics category before this case broke. A tumor appea
$0.013413
Est. cost (USD)
Result preview
The CagriSema vs tirzepatide head-to-head is exactly the comparison my retatrutide analysis was built around, and those REIMAGINE 4 numbers tell you something important about where Novo actually stands.
Even if CagriSema edges tirzepatide in that 68-week T2D readout, the ceiling it's competing toward is already obsolete. TRIUMPH-1 puts retatrutide at 28.3% mean total body weight loss in a heavier
$0.013917
Est. cost (USD)
Result preview
The 55% direct-to-consumer figure is striking, but the more consequential number sitting underneath it is that Lilly launched Employer Connect on March 5, 2026 at $449 per dose through 15+ program administrators including GoodRx, Cost Plus Drugs, and Teladoc. That channel is not a patient access program. It's a deliberate structural bypass of PBM intermediary economics, and it's now operating at s
$0.012471
Est. cost (USD)
Result preview
The comparison is striking but the framing stops one step short of where it gets complicated.
With implants you don't just have price, you've got traceability as a core part of the cost problem. CMS-1849-F just dropped UDI capture requirements into the Public Health and Data Exchange objective, which means hospitals now have to track device data through their EHR and report it out. That's not not
$0.012081
Est. cost (USD)
Result preview
The public comment framing is where this gets complicated. Soliciting input on procedural alignment sounds like standard regulatory housekeeping, but the actual policy mechanism buried inside RAPID is a clock synchronization event, not just a process efficiency. When FDA clearance triggers CMS's NCD workflow on the same day, you've converted reimbursement uncertainty from a years-long post-clearan
$0.010824
Est. cost (USD)
Result preview
The prison-run home health agency is the kind of case that travels well politically, which is exactly why it lands in a White House Task Force highlight reel.
What gets less attention is that the enforcement model behind these cases, which I dug into at https://www.onhealthcare.tech/p/the-medicaid-fraud-war-room-stopped-4f8?utm_source=x&utm_medium=reply&utm_content=2085883598419157495&utm_campaig